Expert Perspectives in Monitoring and Management Strategies for CRS, ICANS, and Other Long-Term Toxicities Associated with CAR T-cell Therapy

Author(s):

Elias Jabbour, MD,Evandro D. Bezerra, MD

The panel explores laboratory parameters routinely monitored for CRS and ICANS, including monitoring frequency, and discusses prophylactic measures and safety management strategies employed to address these complications in CAR-T therapy.

EP: 1.Overview of CAR T-cell Therapies in R/R B-cell ALL

EP: 2.CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel

EP: 3.Considerations for Dosing and Lymphodepletion with CAR T-cell Therapy in R/R ALL

EP: 4.Expert Perspectives on CAR T-Cell Therapy Logistics: Collection to Treatment

EP: 5.Overview of Available Treatment Options in R/R B-cell ALL

EP: 6.Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives

EP: 7.Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data

EP: 8.Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL

EP: 9.Expert Perspectives on Bridging Therapy Strategies Prior to CAR T-cell Therapy

EP: 10.Sequencing Strategies with CAR T-cell Therapy in Patients with or without Prior Blinatumomab Treatment

EP: 11.Translating Data Updates from FELIX and ZUMA-3 to the Clinical Practice Setting

EP: 12.Expert Perspectives on the Potential Impact of Obe-cel on the Treatment Landscape for R/R ALL

EP: 13.Treatment Approaches with Consolidation and Maintenance Post CAR T-cell Therapy

EP: 14.Future Perspectives on CAR T-cell Therapy in R/R B-cell ALL

EP: 15.Frequency, Correlation with Clinical Outcomes, and Risk Factors for Severe CRS and ICANS in CAR T-cell Therapy

Now Viewing

EP: 16.Expert Perspectives in Monitoring and Management Strategies for CRS, ICANS, and Other Long-Term Toxicities Associated with CAR T-cell Therapy

EP: 17.Logistical and Access Challenges with CAR T-cell Therapy in R/R ALL

EP: 18.Strategies and Resources for Overcoming Barriers to CAR T-Cell Therapy

EP: 19.Role of Multidisciplinary Team & Logistics of CAR T-cell Therapy Administration in the Inpatient or Outpatient Setting

EP: 20.Key Takeaways and Clinical Pearls in the Treatment of R/R ALL

Video content above is prompted by the following:

What labs do you routinely monitor for CRS and ICANs – and how frequently?
What type of prophylaxis and/or safety management are you applying to address CRS and ICANs?
Does your institution have a standard operating procedure or guideline?
- What percentage of your patients have required either steroids, tocilizumab, and/or anakinra for CAR-related toxicities?
What are some other pertinent acute and long-term toxicities of CAR T-cell therapy to monitor for?
Do you utilize antimicrobial prophylaxis, growth factor agents and IV immunoglobulin in your practice?
When weighing treatment options, how heavily is CAR-T AE profile considered?
- Does the safety profile of obe-cel change your perspective of using CAR-T? If so, how may it potentially affect your decision making?